Jotte, R., Conkling, P. R., Reynolds, C., Shah, C., Galsky, M., Klein, L., … Renschler, M. (2009). 9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial. In European Journal of Cancer Supplements (Vol. 7, pp. 540–541). Elsevier BV. https://doi.org/10.1016/s1359-6349(09)71833-6

Jotte, R., P. R. Conkling, C. Reynolds, C. Shah, M. Galsky, L. Klein, J. F. Fitzgibbons, R. McNally, J. W. Oliver, and M. Renschler. “9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial.” In European Journal of Cancer Supplements, 7:540–41. Elsevier BV, 2009. https://doi.org/10.1016/s1359-6349(09)71833-6.

Jotte R, Conkling PR, Reynolds C, Shah C, Galsky M, Klein L, et al. 9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial. In: European Journal of Cancer Supplements. Elsevier BV; 2009. p. 540–1.

Jotte, R., et al. “9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial.” European Journal of Cancer Supplements, vol. 7, no. 2, Elsevier BV, 2009, pp. 540–41. Crossref, doi:10.1016/s1359-6349(09)71833-6.

Jotte R, Conkling PR, Reynolds C, Shah C, Galsky M, Klein L, Fitzgibbons JF, McNally R, Oliver JW, Renschler M. 9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial. European Journal of Cancer Supplements. Elsevier BV; 2009. p. 540–541.